169 related articles for article (PubMed ID: 28302509)
41. Inhibition of forebrain μ-opioid receptor signaling by low concentrations of rimonabant does not require cannabinoid receptors and directly involves μ-opioid receptors.
Zádor F; Otvös F; Benyhe S; Zimmer A; Páldy E
Neurochem Int; 2012 Aug; 61(3):378-88. PubMed ID: 22613132
[TBL] [Abstract][Full Text] [Related]
42. Synthesis and pharmacological evaluation of novel octahydro-1H-pyrido[1,2-a]pyrazine as mu-opioid receptor antagonists.
Le Bourdonnec B; Goodman AJ; Graczyk TM; Belanger S; Seida PR; DeHaven RN; Dolle RE
J Med Chem; 2006 Dec; 49(25):7290-306. PubMed ID: 17149859
[TBL] [Abstract][Full Text] [Related]
43. Preclinical disposition (in vitro) of novel μ-opioid receptor selective antagonists.
Mitra P; Venitz J; Yuan Y; Zhang Y; Gerk PM
Drug Metab Dispos; 2011 Sep; 39(9):1589-96. PubMed ID: 21685245
[TBL] [Abstract][Full Text] [Related]
44. Comparison of [Dmt1]DALDA and DAMGO in binding and G protein activation at mu, delta, and kappa opioid receptors.
Zhao GM; Qian X; Schiller PW; Szeto HH
J Pharmacol Exp Ther; 2003 Dec; 307(3):947-54. PubMed ID: 14534366
[TBL] [Abstract][Full Text] [Related]
45. Discovery of Novel µ-Opioid Receptor Inverse Agonist from a Combinatorial Library of Tetrapeptides through Structure-Based Virtual Screening.
Poli G; Dimmito MP; Mollica A; Zengin G; Benyhe S; Zador F; Stefanucci A
Molecules; 2019 Oct; 24(21):. PubMed ID: 31717871
[TBL] [Abstract][Full Text] [Related]
46. Structure-activity relationships for SNC80 and related compounds at cloned human delta and mu opioid receptors.
Knapp RJ; Santoro G; De Leon IA; Lee KB; Edsall SA; Waite S; Malatynska E; Varga E; Calderon SN; Rice KC; Rothman RB; Porreca F; Roeske WR; Yamamura HI
J Pharmacol Exp Ther; 1996 Jun; 277(3):1284-91. PubMed ID: 8667189
[TBL] [Abstract][Full Text] [Related]
47. Molecular modeling studies to predict the possible binding modes of endomorphin analogs in mu opioid receptor.
Liu X; Kai M; Jin L; Wang R
Bioorg Med Chem Lett; 2009 Sep; 19(18):5387-91. PubMed ID: 19679474
[TBL] [Abstract][Full Text] [Related]
48. Deciphering the molecular basis of the kappa opioid receptor selectivity: A Molecular Dynamics study.
Saleh AH; Abdelwaly A; Darwish KM; Eissa AAHM; Chittiboyina A; Helal MA
J Mol Graph Model; 2021 Jul; 106():107940. PubMed ID: 34015577
[TBL] [Abstract][Full Text] [Related]
49. Molecular dynamics of fentanyl bound to μ-opioid receptor.
Lipiński PFJ; Jarończyk M; Dobrowolski JC; Sadlej J
J Mol Model; 2019 May; 25(5):144. PubMed ID: 31053968
[TBL] [Abstract][Full Text] [Related]
50. A pharmacological comparison of the cloned frog and human mu opioid receptors reveals differences in opioid affinity and function.
Brasel CM; Sawyer GW; Stevens CW
Eur J Pharmacol; 2008 Dec; 599(1-3):36-43. PubMed ID: 18930720
[TBL] [Abstract][Full Text] [Related]
51. The Pharmacological Heterogeneity of Nepenthone Analogs in Conferring Highly Selective and Potent κ-Opioid Agonistic Activities.
Li W; Long JD; Qian YY; Long Y; Xu XJ; Wang YJ; Shen Q; Wang ZN; Yang XC; Xiao L; Sun HP; Xu YL; Chen YY; Xie Q; Wang YH; Shao LM; Liu JG; Qiu ZB; Fu W
ACS Chem Neurosci; 2017 Apr; 8(4):766-776. PubMed ID: 28033462
[TBL] [Abstract][Full Text] [Related]
52. Synthesis and opioid activity of conformationally constrained dynorphin A analogues. 2. Conformational constraint in the "address" sequence.
Arttamangkul S; Ishmael JE; Murray TF; Grandy DK; DeLander GE; Kieffer BL; Aldrich JV
J Med Chem; 1997 Apr; 40(8):1211-8. PubMed ID: 9111295
[TBL] [Abstract][Full Text] [Related]
53. K303⁶·⁵⁸ in the μ opioid (MOP) receptor is important in conferring selectivity for covalent binding of β-funaltrexamine (β-FNA).
DiMattio KM; Chen C; Shi L; Liu-Chen LY
Eur J Pharmacol; 2015 Feb; 748():93-100. PubMed ID: 25481857
[TBL] [Abstract][Full Text] [Related]
54. Exploring the structure determinants of pyrazinone derivatives as PDE5 3HC8 inhibitors: an in silico analysis.
Li Y; Wu W; Ren H; Wang J; Zhang S; Li G; Yang L
J Mol Graph Model; 2012 Sep; 38():112-22. PubMed ID: 23085160
[TBL] [Abstract][Full Text] [Related]
55. Design, synthesis, in vitro evaluation, and molecular modeling studies of N-substituted benzomorphans, analogs of LP2, as novel MOR ligands.
Costanzo G; Patamia V; Turnaturi R; Parenti C; Zagni C; Lombino J; Amata E; Marrazzo A; Pasquinucci L; Rescifina A
Chem Biol Drug Des; 2023 Jun; 101(6):1382-1392. PubMed ID: 36813756
[TBL] [Abstract][Full Text] [Related]
56. Binding site of loperamide: automated docking of loperamide in human mu- and delta-opioid receptors.
di Bosco AM; Grieco P; Diurno MV; Campiglia P; Novellino E; Mazzoni O
Chem Biol Drug Des; 2008 Apr; 71(4):328-35. PubMed ID: 18284554
[TBL] [Abstract][Full Text] [Related]
57. Molecular modeling studies to characterize N-phenylpyrimidin-2-amine selectivity for CDK2 and CDK4 through 3D-QSAR and molecular dynamics simulations.
Chohan TA; Chen JJ; Qian HY; Pan YL; Chen JZ
Mol Biosyst; 2016 Apr; 12(4):1250-68. PubMed ID: 26883408
[TBL] [Abstract][Full Text] [Related]
58. Profiling the structural determinants for the selectivity of representative factor-Xa and thrombin inhibitors using combined ligand-based and structure-based approaches.
Bhunia SS; Roy KK; Saxena AK
J Chem Inf Model; 2011 Aug; 51(8):1966-85. PubMed ID: 21761917
[TBL] [Abstract][Full Text] [Related]
59. Reversal of subtype-selectivity and function by the introduction of a para-benzamidyl substituent to N-cyclopropylmethyl nornepenthone.
Kong L; Ning K; Liu X; Lu J; Chen B; Ye R; Li Z; Jiang S; Tang S; Chai JR; Fang Y; Lan Y; Mai X; Xie Q; Liu J; Shao L; Fu W; Wang Y; Li W
Eur J Med Chem; 2023 Oct; 258():115589. PubMed ID: 37413884
[TBL] [Abstract][Full Text] [Related]
60. Understanding the structural requirements of 4-anilidopiperidine analogues for biological activities at mu and delta opioid receptors.
Lee YS; Nyberg J; Moye S; Agnes RS; Davis P; Ma SW; Lai J; Porreca F; Vardanyan R; Hruby VJ
Bioorg Med Chem Lett; 2007 Apr; 17(8):2161-5. PubMed ID: 17329100
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
